Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 1-15 , February 2009

An introduction to the endocannabinoid system: from the early to the latest concepts

References 

  1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society. 1964;86:1646–1647
  2. Mechoulam R, Shvo Y. Hashish. I. The structure of cannabidiol. Tetrahedron. 1963;19:2073–2078
  3. Mechoulam R, Lander N, Varkony TH, et al. Stereochemical requirements for cannabinoid activity. Journal of Medicinal Chemistry. 1980;23:1068–1072
  4. Mechoulam R, Feigenbaum JJ, Lander N, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 1988;44:762–764
  5. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988;34:605–613
  6. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564
  7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65
  8. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008;153:199–215
  9. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949
  10. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50:83–90
  11. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications. 1995;215:89–97
  12. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. The Proceedings of National Academy of Sciences of the United States of America. 2001;98:3662–3665
  13. Bisogno T, Melck D, Bobrov MYu, et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal. 2000;351:817–824
  14. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. The Proceedings of National Academy of Sciences of the United States of America. 2002;99:8400–8405
  15. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. The Journal of Pharmacology and Experimental Therapeutics. 2002;301:1020–1024
  16. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686–691
  17. Di Marzo V, De Petrocellis L, Sugiura T, et al. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochemical and Biophysical Research Communications. 1996;227:281–288
  18. Bisogno T, Sepe N, Melck D, et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical Journal. 1997;322:671–677
  19. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773–778
  20. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. The Journal of Neuroscience. 1997;17:1226–1242
  21. Bisogno T, Melck D, De Petrocellis L, et al. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. Journal of Neurochemistry. 1999;72:2113–2119
  22. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–87
  23. Karlsson M, Contreras JA, Hellman U, et al. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. The Journal of Biological Chemistry. 1997;272:27218–27223
  24. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. The Proceedings of National Academy of Sciences of the United States of America. 2002;99:10819–10824
  25. Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. The Journal of Cell Biology. 2003;163:463–468
  26. Okamoto Y, Morishita J, Tsuboi K, et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. The Journal of Biological Chemistry. 2004;279:5298–5305
  27. Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094–1097
  28. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport. 2000;11:1231–1235
  29. Bisogno T, Maccarrone M, De Petrocellis L, et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. European Journal of Biochemistry. 2001;268:1982–1989
  30. Maione S, Morera E, Marabese I, et al, Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. British Journal of Pharmacology 2008; 155(5): 775–782.
  31. Fowler CJ, Ghafouri N. Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?. Pharmacological Research. 2008;58:72–76
  32. Ortega-Gutiérrez S, Hawkins EG, Viso A, et al. Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry. 2004;43:8184–8190
  33. Glaser ST, Abumrad NA, Fatade F, et al. Evidence against the presence of an Anandamide transporter. The Proceedings of National Academy of Sciences of the United States of America. 2003;100:4269–4274
  34. Bracey MH, Hanson MA, Masuda KR, et al. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science. 2002;298:1793–1796
  35. Di Marzo V, De Petrocellis L. Non-CB1, Non-CB2 Receptors for Endocannabinoids. In:  Oinavi ES,  Sugiura T,  Di Marzo V editor. Endocannabinoids. Taylor & Francis CRC Press; 2006;p. 151–174
  36. Begg M, Pacher P, Bátkai S, et al. Evidence for novel cannabinoid receptors. Pharmacology & Therapeutics. 2005;106:133–145
  37. Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology. 2001;60:155–163
  38. Offertáler L, Mo FM, Bátkai S, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology. 2003;63:699–705
  39. Kimura T, Ohta T, Watanabe K, et al. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biological & Pharmaceutical Bulletin. 1998;21:224–226
  40. Xiong W, Hosoi M, Koo BN, et al. Anandamide inhibition of 5-HT3A receptors varies with receptor density and desensitization. Molecular Pharmacology. 2008;73:314–322
  41. Christopoulos A, Wilson K. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. Brain Research. 2001;915:70–78
  42. Lozovaya N, Yatsenko N, Beketov A, et al. Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. Journal of Neuroscience. 2005;25:7499–7506
  43. Hejazi N, Zhou C, Oz M, et al. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Molecular Pharmacology. 2006;69:991–997
  44. Oz M, Ravindran A, Diaz-Ruiz O, et al. The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. The Journal of Pharmacology and Experimental Therapeutics. 2003;306:1003–1010
  45. Oz M. Receptor-independent effects of endocannabinoids on ion channels. Current Pharmaceutical Design. 2006;12:227–239
  46. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452–457
  47. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics. 2007;114:13–33
  48. Pacher P, Bátkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. The Journal of Physiology. 2004;558:647–657
  49. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out?. Trends in Pharmacological Sciences. 2008;29:229–233
  50. De Petrocellis L, Starowicz K, Moriello AS, et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Experimental Cell Research. 2007;313:1911–1920
  51. De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. The Journal of Pharmacology and Experimental Therapeutics. 2008;325:1007–1015
  52. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology. 2007;152:1092–1101
  53. Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. The Proceedings of National Academy of Sciences of the United States of America. 2008;105:2699–2704
  54. Waldeck-Weiermair M, Zoratti C, Osibow K, et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. Journal of Cell Science. 2008;121:1704–1717
  55. Oka S, Nakajima K, Yamashita A, et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochemical and Biophysical Research Communications. 2007;362:928–934
  56. Henstridge CM, Balenga NA, Ford LA et al. The GPR55 ligand L-{alpha}-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. The FASEB Journal, in press.
  57. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. British Journal of Pharmacology. 2007;152:825–831
  58. Kearn CS, Blake-Palmer K, Daniel E, et al. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Molecular Pharmacology. 2005;67:1697–1704
  59. Ellis J, Pediani JD, Canals M, et al. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. The Journal of Biological Chemistry. 2006;281:38812–38824
  60. Carriba P, Ortiz O, Patkar K, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology. 2007;32:2249–2259
  61. Ryberg E, Vu HK, Larsson N, et al. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Letters. 2005;579:259–264
  62. O'Sullivan SE, Randall MD, Gardiner SM. The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase. The Journal of Pharmacology and Experimental Therapeutics. 2007;321:663–672
  63. Bouaboula M, Hilairet S, Marchand J, et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology. 2005;517:174–181
  64. Rockwell CE, Snider NT, Thompson JT, et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Molecular Pharmacology. 2006;70:101–111
  65. Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cellular Molecular Life Sciences. 2007;64:219–229
  66. Artmann A, Petersen G, Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochimica et Biophysica Acta. 2008;1781:200–212
  67. O'Sullivan SE, Tarling EJ, Bennett AJ, et al. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications. 2005;337:824–831
  68. Randall MD, Kendall DA, Bennett AJ, et al. Rimonabant in obese patients with type 2 diabetes. Lancet. 2007;369:555
  69. Alexander SP, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. British Journal of Pharmacology. 2007;152:602–623
  70. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90–93
  71. Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. The Journal of Physiology. 2005;564:541–547
  72. Thabuis C, Tissot-Favre D, Bezelgues JB et al. Biological functions and metabolism of oleoylethanolamide. Lipids 2008; 43(10): 887–894.
  73. Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metababolism. 2006;3:167–175
  74. Ning Y, O'Neill K, Lan H, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. British Journal of Pharmacology, in press.
  75. LoVerme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sciences. 2005;77:1685–1698
  76. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal. 2001;358:249–255
  77. Costa B, Comelli F, Bettoni I et al. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008; 139(3): 541–550.
  78. De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Letters. 2001;506:253–256
  79. Smart D, Jonsson KO, Vandevoorde S, et al. ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. British Journal of Pharmacology. 2002;136:452–458
  80. Ho WS, Barrett DA, Randall MD. ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. British Journal of Pharmacology, in press.
  81. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology. 1998;353:23–31
  82. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413:527–531
  83. Huang SM, Bisogno T, Petros TJ, et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. The Journal of Biological Chemistry. 2001;276:42639–42644
  84. Milman G, Maor Y, Abu-Lafi S, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. The Proceedings of National Academy of Sciences of the United States of America. 2006;103:2428–2433
  85. Tan B, Bradshaw HB, Rimmerman N, et al. Targeted lipidomics: discovery of new fatty acyl amides. The AAPS Journal. 2006;8:E461–E465
  86. Rimmerman N, Bradshaw HB, Hughes HV, et al. N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons. Molecular Pharmacology. 2008;74:213–224
  87. Chu CJ, Huang SM, De Petrocellis L, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. The Journal of Biological Chemistry. 2003;278:13633–13639
  88. De Petrocellis L, Chu CJ, Moriello AS, et al. Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. British Journal of Pharmacology. 2004;143:251–256
  89. Saghatelian A, Trauger SA, Want EJ, et al. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry. 2004;43:14332–14339
  90. Saghatelian A, McKinney MK, Bandell M, et al. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry. 2006;45:9007–9015
  91. Leung D, Saghatelian A, Simon GM, et al. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry. 2006;45:4720–4726
  92. Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. The Proceedings of National Academy of Sciences of the United States of America. 2006;103:13345–13350
  93. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008;54:1–7
  94. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. The Journal of Biological Chemistry. 2006;281:26465–26472
  95. Sun YX, Tsuboi K, Okamoto Y, et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochemical Journal. 2004;380:749–756
  96. Di Marzo V, Bisogno T, Sugiura T, et al. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochemical Journal. 1998;331:15–19
  97. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology. 2007;14:1347–1356
  98. Mulder AM, Cravatt BF. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines. Biochemistry. 2006;45:11267–11277
  99. Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. The Journal of Biological Chemistry. 2006;281:36569–36578
  100. Tsuboi K, Sun YX, Okamoto Y, et al. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. The Journal of Biological Chemistry. 2005;280:11082–11092
  101. Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukotrienes and Essential Fatty Acids. 2002;66:211–220
  102. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. British Journal of Pharmacology. 2008;153:410–419
  103. Matias I, Chen J, De Petrocellis L, et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. The Journal of Pharmacology and Experimental Therapeutics. 2004;309:745–757
  104. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. British Journal of Pharmacology. 2008;154:1079–1093
  105. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. The Journal of Biological Chemistry. 2000;275:33744–33749
  106. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. The Journal of Biological Chemistry. 2002;277:44877–44885
  107. Nirodi CS, Crews BC, Kozak KR, et al. The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. The Proceedings of National Academy of Sciences of the United States of America. 2004;101:1840–1845
  108. Vila A, Rosengarth A, Piomelli D, et al. Hydrolysis of prostaglandin glycerol esters by the endocannabinoid-hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide hydrolase. Biochemistry. 2007;46:9578–9585
  109. Ueda N, Yamamoto K, Yamamoto S, et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochimica et Biophysica Acta. 1995;1254:127–134
  110. Edgemond WS, Hillard CJ, Falck JR, et al. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Molecular Pharmacology. 1998;54:180–188
  111. van der Stelt M, van Kuik JA, Bari M, et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. Journal of Medicinal Chemistry. 2002;45:3709–3720
  112. Bornheim LM, Kim KY, Chen B, et al. Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochemical Pharmacology. 1995;50:677–686
  113. Snider NT, Sikora MJ, Sridar C et al. The Endocannabinoid Anandamide is a substrate for the human polymorphic Cytochrome P450 2D6. The Journal of Pharmacology and Experimental Therapeutics 321(2): 590–597.
  114. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews Drug Discovery. 2008;7:438–455
  115. Fowler CJ. ‘The tools of the trade’–an overview of the pharmacology of the endocannabinoid system. Current Pharmaceutical Design. 2008;14:2254–2265
  116. Ross RA. Allosterism and cannabinoid CB(1) receptors: the shape of things to come. Trends in Pharmacological Sciences. 2007;28:567–572
  117. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51:1356–1367
  118. Soria-Gómez E, Matias I, Rueda-Orozco PE, et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology. 2007;151:1109–1116
  119. Dipatrizio NV, Simansky KJ. Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2008; 295(5): R1409–R1414.
  120. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677–687
  121. Bifulco M, Laezza C, Valenti M, et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. The FASEB Journal. 2004;18:1606–1608
  122. Nithipatikom K, Endsley MP, Isbell MA, et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research. 2004;64:8826–8830
  123. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut. 2006;55:1373–1376
  124. Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic & Clinical Pharmacology & Toxicology. 2007;101:287–293
  125. Fezza F, De Simone C, Amadio D, et al. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcellular Biochemistry. 2008;49:101–132
  126. Niehaus JL, Liu Y, Wallis KT, et al. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Molecular Pharmacology. 2007;72:1557–1566
  127. He F, Qiao ZH, Cai J, et al. Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration signaling of a G protein-coupled receptor. Molecular Pharmacology. 2007;72:1289–1300
  128. Heimann AS, Gomes I, Dale CS, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proceedings of National Academy of Sciences of the United States of America. 2007;104:20588–20593
  129. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Current Medicinal Chemistry. 1999;6:635–664
  130. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation. 2005;115:1298–1305
  131. Ashton JC, Glass M. The Cannabinoid CB2 Receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology. 2007;5:73–80
  132. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–332
  133. Onaivi ES, Ishiguro H, Gong JP, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE. 2008;3:e1640
  134. Guzmán M, Sánchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacology & Therapeutics. 2002;95:175–184
  135. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery. 2004;3:771–784
  136. Pertwee RG. Pharmacological actions of cannabinoids. Handbook of Experimental Pharmacology. 2005;(168):1–51
  137. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58:389–462
  138. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal. 2005;7:E625–E654
  139. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology. 2007;18:129–140
  140. Bisogno T, Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacological Research. 2007;56:428–442
  141. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addiction Biology. 2008;13:196–212
  142. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nature Medicine. 2008;14:923–930
  143. Howlett AC. Cannabinoid receptor signaling. Handbook of Experimental Pharmacology. 2005;168:53–79
  144. Mackie K. Signaling via CNS cannabinoid receptors. Molecular and Cellular Endocrinology. 2008;286:S60–S65
  145. Nyilas R, Dudok B, Urbán GM, et al. Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. The Journal of Neuroscience. 2008;28:1058–1063
  146. Egertová M, Simon GM, Cravatt BF, et al. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. The Journal of Comparative Neurology. 2008;506:604–615
  147. Cristino L, Starowicz K, De Petrocellis L, et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience. 2008;151:955–968
  148. Mezey E, Tóth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proceedings of National Academy of Sciences of the United States of America. 2000;97:3655–3660
  149. Cristino L, de Petrocellis L, Pryce G, et al. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139:1405–1415
  150. Marinelli S, Di Marzo V, Florenzano F, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology. 2007;32:298–308
  151. Di Marzo V, Cristino L. Why endocannabinoids are not all alike. Nature Neuroscience. 2008;11:124–126
  152. Maccarrone M, Rossi S, Bari M, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nature Neuroscience. 2008;11:152–159
  153. van der Stelt M, Trevisani M, Vellani V, et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. The EMBO Journal. 2005;24:3026–3037

PII: S1521-690X(08)00143-7

doi: 10.1016/j.beem.2008.10.013

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 1-15 , February 2009

Article Tools

* Image Usage & Resolution